Global Migraine Therapeutics Market Size study & Forecast, by Therapeutics (Pain-relieving Medications, Preventive Medications), by Route of Administration (Oral & Nasal, Injectables), and Regional Analysis, 2022-2029
Global Migraine Therapeutics Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029.A crippling neurological condition called migraine is characterised by frequent occurrences of excruciatingly painful, throbbing headaches that can last up to three days. These headaches, which are typically unilateral, can last anywhere between four hours and three days. Pain is frequently accompanied by additional symptoms such perspiration, diarrhoea, tingling or numbness in the legs or extremities, nausea, vomiting, increased sensitivity to sound (phonophobia), increased sensitivity to light (photophobia), and vomiting.. To treat migraine, migraine therapeutics are being used. The Migraine Therapeutics market is expanding because of factors such as growing awareness about Migraine and its treatment options and increasing prevalence of Migraines along with high unmet needs. However, adverse effects of drugs and lack of proper diagnosis and increasing undiagnosed cases may halt market growth.
The American Food and Drug Administration (FDA) approved Lundbeck's VYEPTI (eptinezumab-jjmr) in February 2020 for the adult population's migraine prevention. Additionally, in May 2021, the United States Food and Drug Administration (FDA) approved Biohaven Pharmaceutical Holding Company Ltd.'s NURTEC ODT (rimegepant 75 mg) for the treatment of migraines before they start. Adult patients with episodic migraine, such as those who encounter fewer than 15 headache days per month, are advised to use NURTEC ODT. Over the projected term, these approvals drive the study market's expansion. In addition, AbbVie reported favourable results from a phase 3 clinical trial testing atogepant (marketed as QULIPTA in the US) for the prevention of chronic migraine in adults in March 2022. It is an antagonist of the CGRP receptor that is taken orally (gepant). For both the 60 mg once daily (QD) and the 30 mg twice daily (BID) doses, the medication achieved the trial's primary aim of a statistically significant reduction from baseline in mean monthly migraine days compared to placebo over the course of the 12-week treatment period. The successful launch of this Therapeutics may provide patients with an alternative option.
The key regions considered for the Global Migraine Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World.Due to the dominance of branded Therapeutics and the rising prevalence of diseases in the region, North America dominated the space in terms of revenue. In 2020, there will be approximately 37.3 million diabetics in the United States, including 28.7 million instances that have been diagnosed and 8.5 million cases that have not. Due to factors like growing geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active involvement of the government and nonprofit organisations in the market space, Asia Pacific is predicted to experience significant growth during the forecast period..
Major market players included in this report are:
Amgen
Abbvie Inc.
AstraZeneca
Eli Lilly and Co.
GlaxoSmithKline
Merck & Co., Inc.
Pfizer
Bausch Health
Teva Pharmac
Novartis AGeuticals
Recent Developments in the Market:
In February 2022, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recently approved Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, from Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. The oral dissolving tablet form of Rimegepant, which comes at a dose of 75 mg, is advised for use in the prevention of episodic migraine in adults who experience at least four migraine attacks per month as well as in the acute treatment of migraine with or without aura in adults.
In Aug 2022, The U.S. Food and Drug Administration (FDA) approved an expanded label for Eli Lilly and Company's rapid-acting Migraine Therapeutics, Lyumjev® (Migraine Therapeutics lispro-AABC injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous Migraine Therapeutics infusion (CSII) with a Migraine Therapeutics pump.
In July 2021, BioDelivery Sciences announced the introduction of new drug, Elyxyb.It is one of the first adult ready-to-use oral solutions for the acute treatment of migraine, with or without aura, that the Food and Drug Administration has approved. .
Global Migraine Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Therapeutics, Route of Administration, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Therapeutics offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapeutics:
Pain-relieving Medications
Preventive Medications
By Route of Administration:
Oral & Nasal
Injectables
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
The American Food and Drug Administration (FDA) approved Lundbeck's VYEPTI (eptinezumab-jjmr) in February 2020 for the adult population's migraine prevention. Additionally, in May 2021, the United States Food and Drug Administration (FDA) approved Biohaven Pharmaceutical Holding Company Ltd.'s NURTEC ODT (rimegepant 75 mg) for the treatment of migraines before they start. Adult patients with episodic migraine, such as those who encounter fewer than 15 headache days per month, are advised to use NURTEC ODT. Over the projected term, these approvals drive the study market's expansion. In addition, AbbVie reported favourable results from a phase 3 clinical trial testing atogepant (marketed as QULIPTA in the US) for the prevention of chronic migraine in adults in March 2022. It is an antagonist of the CGRP receptor that is taken orally (gepant). For both the 60 mg once daily (QD) and the 30 mg twice daily (BID) doses, the medication achieved the trial's primary aim of a statistically significant reduction from baseline in mean monthly migraine days compared to placebo over the course of the 12-week treatment period. The successful launch of this Therapeutics may provide patients with an alternative option.
The key regions considered for the Global Migraine Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World.Due to the dominance of branded Therapeutics and the rising prevalence of diseases in the region, North America dominated the space in terms of revenue. In 2020, there will be approximately 37.3 million diabetics in the United States, including 28.7 million instances that have been diagnosed and 8.5 million cases that have not. Due to factors like growing geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active involvement of the government and nonprofit organisations in the market space, Asia Pacific is predicted to experience significant growth during the forecast period..
Major market players included in this report are:
Amgen
Abbvie Inc.
AstraZeneca
Eli Lilly and Co.
GlaxoSmithKline
Merck & Co., Inc.
Pfizer
Bausch Health
Teva Pharmac
Novartis AGeuticals
Recent Developments in the Market:
In February 2022, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recently approved Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, from Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. The oral dissolving tablet form of Rimegepant, which comes at a dose of 75 mg, is advised for use in the prevention of episodic migraine in adults who experience at least four migraine attacks per month as well as in the acute treatment of migraine with or without aura in adults.
In Aug 2022, The U.S. Food and Drug Administration (FDA) approved an expanded label for Eli Lilly and Company's rapid-acting Migraine Therapeutics, Lyumjev® (Migraine Therapeutics lispro-AABC injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous Migraine Therapeutics infusion (CSII) with a Migraine Therapeutics pump.
In July 2021, BioDelivery Sciences announced the introduction of new drug, Elyxyb.It is one of the first adult ready-to-use oral solutions for the acute treatment of migraine, with or without aura, that the Food and Drug Administration has approved. .
Global Migraine Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Therapeutics, Route of Administration, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Therapeutics offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapeutics:
Pain-relieving Medications
Preventive Medications
By Route of Administration:
Oral & Nasal
Injectables
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Migraine Therapeutics Market, by Region, 2019-2029 (USD Billion)
1.2.2. Migraine Therapeutics Market, by Therapeutics, 2019-2029 (USD Billion)
1.2.3. Migraine Therapeutics Market, by Route of Administration, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL MIGRAINE THERAPEUTICS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL MIGRAINE THERAPEUTICS MARKET DYNAMICS
3.1. Migraine Therapeutics Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Growing Awareness about Migraine and its Treatment Options
3.1.1.2. Increasing Prevalence of Migraines along with High Unmet Needs
3.1.2. Market Challenges
3.1.2.1. Adverse Effects of Drugs
3.1.2.2. Lack of Proper Diagnosis and Increasing Undiagnosed Cases
3.1.3. Market Opportunities
3.1.3.1. Increasing R&D Expenditures Leading to High Pipeline Products
CHAPTER 4. GLOBAL MIGRAINE THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
CHAPTER 5. RISK ASSESSMENT: COVID-19 IMPACT
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
CHAPTER 6. GLOBAL MIGRAINE THERAPEUTICS MARKET, BY THERAPEUTICS
6.1. Market Snapshot
6.2. Global Migraine Therapeutics Market by Therapeutics, Performance - Potential Analysis
6.3. Global Migraine Therapeutics Market Estimates & Forecasts by Therapeutics, 2019-2029 (USD Billion)
6.4. Migraine Therapeutics Market, Sub Segment Analysis
6.4.1. Pain-relieving Medications
6.4.2. Preventive Medications
CHAPTER 7. GLOBAL MIGRAINE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Market Snapshot
7.2. Global Migraine Therapeutics Market by Route of Administration, Performance - Potential Analysis
7.3. Global Migraine Therapeutics Market Estimates & Forecasts by Route of Administration, 2019-2029 (USD Billion)
7.4. Migraine Therapeutics Market, Sub Segment Analysis
7.4.1. Oral & Nasal
7.4.2. Injectables
CHAPTER 8. GLOBAL MIGRAINE THERAPEUTICS MARKET, REGIONAL ANALYSIS
8.1. Migraine Therapeutics Market, Regional Market Snapshot
8.2. North America Migraine Therapeutics Market
8.2.1. U.S. Migraine Therapeutics Market
8.2.1.1. Therapeutics breakdown estimates & forecasts, 2019-2029
8.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Migraine Therapeutics Market
8.3. Europe Migraine Therapeutics Market Snapshot
8.3.1. U.K. Migraine Therapeutics Market
8.3.2. Germany Migraine Therapeutics Market
8.3.3. France Migraine Therapeutics Market
8.3.4. Spain Migraine Therapeutics Market
8.3.5. Italy Migraine Therapeutics Market
8.3.6. Rest of Europe Migraine Therapeutics Market
8.4. Asia-Pacific Migraine Therapeutics Market Snapshot
8.4.1. China Migraine Therapeutics Market
8.4.2. India Migraine Therapeutics Market
8.4.3. Japan Migraine Therapeutics Market
8.4.4. Australia Migraine Therapeutics Market
8.4.5. South Korea Migraine Therapeutics Market
8.4.6. Rest of Asia Pacific Migraine Therapeutics Market
8.5. Latin America Migraine Therapeutics Market Snapshot
8.5.1. Brazil Migraine Therapeutics Market
8.5.2. Mexico Migraine Therapeutics Market
8.6. Rest of The World Migraine Therapeutics Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Amgen
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Abbvie Inc.
9.2.3. AstraZeneca
9.2.4. Eli Lilly and Co.
9.2.5. GlaxoSmithKline
9.2.6. Merck & Co., Inc.
9.2.7. Pfizer
9.2.8. Bausch Health
9.2.9. Teva Pharmaceuticals
9.2.10. Novartis AG
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Migraine Therapeutics Market, by Region, 2019-2029 (USD Billion)
1.2.2. Migraine Therapeutics Market, by Therapeutics, 2019-2029 (USD Billion)
1.2.3. Migraine Therapeutics Market, by Route of Administration, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL MIGRAINE THERAPEUTICS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL MIGRAINE THERAPEUTICS MARKET DYNAMICS
3.1. Migraine Therapeutics Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Growing Awareness about Migraine and its Treatment Options
3.1.1.2. Increasing Prevalence of Migraines along with High Unmet Needs
3.1.2. Market Challenges
3.1.2.1. Adverse Effects of Drugs
3.1.2.2. Lack of Proper Diagnosis and Increasing Undiagnosed Cases
3.1.3. Market Opportunities
3.1.3.1. Increasing R&D Expenditures Leading to High Pipeline Products
CHAPTER 4. GLOBAL MIGRAINE THERAPEUTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
CHAPTER 5. RISK ASSESSMENT: COVID-19 IMPACT
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
CHAPTER 6. GLOBAL MIGRAINE THERAPEUTICS MARKET, BY THERAPEUTICS
6.1. Market Snapshot
6.2. Global Migraine Therapeutics Market by Therapeutics, Performance - Potential Analysis
6.3. Global Migraine Therapeutics Market Estimates & Forecasts by Therapeutics, 2019-2029 (USD Billion)
6.4. Migraine Therapeutics Market, Sub Segment Analysis
6.4.1. Pain-relieving Medications
6.4.2. Preventive Medications
CHAPTER 7. GLOBAL MIGRAINE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
7.1. Market Snapshot
7.2. Global Migraine Therapeutics Market by Route of Administration, Performance - Potential Analysis
7.3. Global Migraine Therapeutics Market Estimates & Forecasts by Route of Administration, 2019-2029 (USD Billion)
7.4. Migraine Therapeutics Market, Sub Segment Analysis
7.4.1. Oral & Nasal
7.4.2. Injectables
CHAPTER 8. GLOBAL MIGRAINE THERAPEUTICS MARKET, REGIONAL ANALYSIS
8.1. Migraine Therapeutics Market, Regional Market Snapshot
8.2. North America Migraine Therapeutics Market
8.2.1. U.S. Migraine Therapeutics Market
8.2.1.1. Therapeutics breakdown estimates & forecasts, 2019-2029
8.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Migraine Therapeutics Market
8.3. Europe Migraine Therapeutics Market Snapshot
8.3.1. U.K. Migraine Therapeutics Market
8.3.2. Germany Migraine Therapeutics Market
8.3.3. France Migraine Therapeutics Market
8.3.4. Spain Migraine Therapeutics Market
8.3.5. Italy Migraine Therapeutics Market
8.3.6. Rest of Europe Migraine Therapeutics Market
8.4. Asia-Pacific Migraine Therapeutics Market Snapshot
8.4.1. China Migraine Therapeutics Market
8.4.2. India Migraine Therapeutics Market
8.4.3. Japan Migraine Therapeutics Market
8.4.4. Australia Migraine Therapeutics Market
8.4.5. South Korea Migraine Therapeutics Market
8.4.6. Rest of Asia Pacific Migraine Therapeutics Market
8.5. Latin America Migraine Therapeutics Market Snapshot
8.5.1. Brazil Migraine Therapeutics Market
8.5.2. Mexico Migraine Therapeutics Market
8.6. Rest of The World Migraine Therapeutics Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Amgen
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Abbvie Inc.
9.2.3. AstraZeneca
9.2.4. Eli Lilly and Co.
9.2.5. GlaxoSmithKline
9.2.6. Merck & Co., Inc.
9.2.7. Pfizer
9.2.8. Bausch Health
9.2.9. Teva Pharmaceuticals
9.2.10. Novartis AG
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
LIST OF TABLES
TABLE 1. Global Migraine Therapeutics Market, report scope
TABLE 2. Global Migraine Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
TABLE 3. Global Migraine Therapeutics Market estimates & forecasts by Therapeutics 2019-2029 (USD Billion)
TABLE 4. Global Migraine Therapeutics Market estimates & forecasts by Route of Administration 2019-2029 (USD Billion)
TABLE 5. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 6. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 7. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 8. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 9. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 10. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 11. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 12. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 13. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 14. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 15. U.S. Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 16. U.S. Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 17. U.S. Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 18. Canada Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 19. Canada Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 20. Canada Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 21. UK Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 22. UK Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 23. UK Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 24. Germany Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 25. Germany Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 26. Germany Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 27. France Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 28. France Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 29. France Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 30. Italy Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 31. Italy Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 32. Italy Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 33. Spain Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 34. Spain Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 35. Spain Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 36. RoE Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 37. RoE Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 38. RoE Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 39. China Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 40. China Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 41. China Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 42. India Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 43. India Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 44. India Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 45. Japan Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 46. Japan Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 47. Japan Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 48. South Korea Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 49. South Korea Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 50. South Korea Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 51. Australia Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 52. Australia Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 53. Australia Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 54. RoAPAC Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 55. RoAPAC Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 56. RoAPAC Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 57. Brazil Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 58. Brazil Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 59. Brazil Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 60. Mexico Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 61. Mexico Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 62. Mexico Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 63. RoLA Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 64. RoLA Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 65. RoLA Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 66. Row Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 67. Row Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 68. Row Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 69. List of secondary sources, used in the study of global Migraine Therapeutics Market
TABLE 70. List of primary sources, used in the study of global Migraine Therapeutics Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
TABLE 1. Global Migraine Therapeutics Market, report scope
TABLE 2. Global Migraine Therapeutics Market estimates & forecasts by Region 2019-2029 (USD Billion)
TABLE 3. Global Migraine Therapeutics Market estimates & forecasts by Therapeutics 2019-2029 (USD Billion)
TABLE 4. Global Migraine Therapeutics Market estimates & forecasts by Route of Administration 2019-2029 (USD Billion)
TABLE 5. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 6. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 7. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 8. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 9. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 10. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 11. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 12. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 13. Global Migraine Therapeutics Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 14. Global Migraine Therapeutics Market by region, estimates & forecasts, 2019-2029 (USD Billion)
TABLE 15. U.S. Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 16. U.S. Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 17. U.S. Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 18. Canada Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 19. Canada Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 20. Canada Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 21. UK Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 22. UK Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 23. UK Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 24. Germany Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 25. Germany Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 26. Germany Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 27. France Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 28. France Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 29. France Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 30. Italy Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 31. Italy Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 32. Italy Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 33. Spain Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 34. Spain Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 35. Spain Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 36. RoE Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 37. RoE Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 38. RoE Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 39. China Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 40. China Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 41. China Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 42. India Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 43. India Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 44. India Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 45. Japan Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 46. Japan Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 47. Japan Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 48. South Korea Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 49. South Korea Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 50. South Korea Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 51. Australia Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 52. Australia Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 53. Australia Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 54. RoAPAC Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 55. RoAPAC Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 56. RoAPAC Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 57. Brazil Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 58. Brazil Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 59. Brazil Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 60. Mexico Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 61. Mexico Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 62. Mexico Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 63. RoLA Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 64. RoLA Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 65. RoLA Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 66. Row Migraine Therapeutics Market estimates & forecasts, 2019-2029 (USD Billion)
TABLE 67. Row Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 68. Row Migraine Therapeutics Market estimates & forecasts by segment 2019-2029 (USD Billion)
TABLE 69. List of secondary sources, used in the study of global Migraine Therapeutics Market
TABLE 70. List of primary sources, used in the study of global Migraine Therapeutics Market
TABLE 71. Years considered for the study
TABLE 72. Exchange rates considered
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
LIST OF FIGURES
FIG 1. Global Migraine Therapeutics Market, research methodology
FIG 2. Global Migraine Therapeutics Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Migraine Therapeutics Market, key trends 2021
FIG 5. Global Migraine Therapeutics Market, growth prospects 2022-2029
FIG 6. Global Migraine Therapeutics Market, porters 5 force model
FIG 7. Global Migraine Therapeutics Market, pest analysis
FIG 8. Global Migraine Therapeutics Market, value chain analysis
FIG 9. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 10. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 11. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 12. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 13. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 14. Global Migraine Therapeutics Market, regional snapshot 2019 & 2029
FIG 15. North America Migraine Therapeutics Market 2019 & 2029 (USD Billion)
FIG 16. Europe Migraine Therapeutics Market 2019 & 2029 (USD Billion)
FIG 17. Asia Pacific Migraine Therapeutics Market 2019 & 2029 (USD Billion)
FIG 18. Latin America Migraine Therapeutics Market 2019 & 2029 (USD Billion)
FIG 19. Global Migraine Therapeutics Market, company Market share analysis (2021)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
FIG 1. Global Migraine Therapeutics Market, research methodology
FIG 2. Global Migraine Therapeutics Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Migraine Therapeutics Market, key trends 2021
FIG 5. Global Migraine Therapeutics Market, growth prospects 2022-2029
FIG 6. Global Migraine Therapeutics Market, porters 5 force model
FIG 7. Global Migraine Therapeutics Market, pest analysis
FIG 8. Global Migraine Therapeutics Market, value chain analysis
FIG 9. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 10. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 11. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 12. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 13. Global Migraine Therapeutics Market by segment, 2019 & 2029 (USD Billion)
FIG 14. Global Migraine Therapeutics Market, regional snapshot 2019 & 2029
FIG 15. North America Migraine Therapeutics Market 2019 & 2029 (USD Billion)
FIG 16. Europe Migraine Therapeutics Market 2019 & 2029 (USD Billion)
FIG 17. Asia Pacific Migraine Therapeutics Market 2019 & 2029 (USD Billion)
FIG 18. Latin America Migraine Therapeutics Market 2019 & 2029 (USD Billion)
FIG 19. Global Migraine Therapeutics Market, company Market share analysis (2021)
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
